Product Surveillance Registry- Deep Brain Stimulation for Epilepsy
NCT ID: NCT01521754
Last Updated: 2020-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
191 participants
OBSERVATIONAL
2012-03-06
2019-06-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose of this observational registry is to evaluate the long-term effectiveness, safety and performance of market-released Medtronic Neuromodulation products for Deep Brain Stimulation (DBS) for the treatment of refractory epilepsy. In addition, healthcare resource use and patient reported outcomes, such as health related quality of life will be assessed.
Enrollment and Duration Patients meeting the eligibility criteria for the implantation of the Medtronic® DBS™ Therapy for Epilepsy will be included in the registry. Approximately 200 patients meeting all the eligibility criteria will be prospectively enrolled over an expected two-year period.
Approximately 30 centers, mainly from across Europe will participate. Center selection could also be extended to sites outside Europe.
Each patient will perform follow-up visits according to clinical practice.
The estimated duration of the registry will be approximately 49 months (24 months for the enrollment phase, 24 months for follow-up visits and 1 month for final data collection).
Inclusion and exclusion criteria Inclusion criteria
* Fulfilling the criteria of labeling indications of Medtronic® DBS™ Therapy for Epilepsy.
* Patient with diagnosis of refractory epilepsy as defined by 1981 ILAE (International League Against Epilepsy) classification, who have been implanted or will be implanted with Medtronic® DBS™ Therapy for Epilepsy.
* For both cohorts, completed at least two full consecutive months diary information on seizure type and frequency prior to DBS implant (seizure type should be classified at least as simple partial, complex partial, partial evolving to secondarily generalized seizures, and generalized). In regard to the prospective cohort, the patient will be conditionally enrolled at the enrolment visit, and the criterion will be reassessed at the baseline visit.
* Patient or patient's legally authorized representative able to understand and to provide written informed consent and/or authorization for access to and use of health information, as required by an institution's IRB/MEC or local law and regulations.
Exclusion criteria
* Incomplete and/or unreliable patient seizure diary based on the physician's judgment
* Patient is currently enrolled in or plans to enroll in any concurrent drug, surgery and/or device study that may confound the results of this registry.
Registry Procedures
After the physician has determined that a patient meets all of the eligibility criteria, the physician will enroll the patient in the registry by completing the Patient Informed Consent or Data Release Consent Form process.
Once enrolled, patients will be followed at least for 24 months or until their discontinuation from the registry.
Follow-up visits will occur according to clinical practice, approximately every 6 months after the first visit post-implant.
Adverse events and/or device events will be reported as they occur.
Data collection will occur at the following time points:
* Enrollment Visit
* Baseline Visit
* Implant Visit
* Follow-up Visits (over a period of minimum two years)
The following follow-up visits are scheduled according to the clinical practice, approximately every 6 months for at least two years or till the closure of the registry.
Primary Objective The primary efficacy objective is to evaluate the change in seizure rate from baseline over 2 years following DBS implant.
Secondary Objectives
* To characterize the demographics of the population undergoing Medtronic® DBS™ Therapy for Epilepsy,
* To assess adverse events related to the device, implant procedure, and/or therapy.
* To characterize seizure type and severity.
* To characterize co-treatments.
* To assess the change in health-related quality of life following DBS by means of QOLIE-31 (Quality of life in epilepsy-31) and SF-36 (Short-form 36).
* To evaluate changes in depression score over time Exploratory objectives
* To assess use of health care resources specifically associated with epilepsy following DBS.
* To characterize DBS implant technique and device/feature utilization.
* To assess the factors that better predict the response level of the DBS therapy.
Sample Size Justification The purpose of the registry is essentially observational and exploratory; hence no sample size calculation was performed.
Safety objectives
* To assess adverse events
* To characterize the incidence of sudden unexpected death in epilepsy (SUDEP)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Perspective
Prospective cohort: new patients who are initially implanted with a Medtronic neurostimulation system on or after a site's activation date. The classification is static and will not change in the case of a re-implant.
No interventions assigned to this group
Retrospective
Retrospective cohort: existing patients comprised the sub-group of patients who were implanted with a Medtronic neurostimulation system prior to a site's activation date. This cohort contains a part of retrospective data and a part of prospective data according to the enrolment date. The classification is static and will not change even when an existing patient will be subsequently re-implanted after the site's activation date.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with diagnosis of refractory epilepsy as defined by 1981 ILAE (International League Against Epilepsy) classification, who have been implanted or will be implanted with Medtronic® DBS™ Therapy for Epilepsy.
* For both cohorts, completed at least two full consecutive months diary information on seizure type and frequency prior to DBS implant (seizure type should be classified at least as simple partial, complex partial, partial evolving to secondarily generalized seizures, and generalized). In regard to the prospective cohort, the patient will be conditionally enrolled at the enrolment visit, and the criterion will be reassessed at the baseline visit.
* Patient or patient's legally authorized representative able to understand and to provide written informed consent and/or authorization for access to and use of health information, as required by an institution's IRB/MEC or local law and regulations.
Exclusion Criteria
* Patient is currently enrolled in or plans to enroll in any concurrent drug, surgery and/or device study that may confound the results of this registry.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MedtronicNeuro
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Boon, MD
Role: PRINCIPAL_INVESTIGATOR
Private
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medizinische Universität Wien
Vienna, , Austria
UZ Gent
Ghent, , Belgium
UZ K.U. Leuven
Leuven, , Belgium
London Health Sciences Centre
London, Ontario, Canada
University & Hospital of Tampere - Neurology and Rehabilitation
Tampere, , Finland
Universitätsklinikum Bonn -AöR-
Bonn, , Germany
University Hospital Freiburg
Freiburg im Breisgau, , Germany
Universitätsklinikum Schleswig-Holstein Campus Kiel
Kiel, , Germany
Klinikum der Universität München -Großhadern
Munich, , Germany
University Hospital Tübingen
Tübingen, , Germany
Országos Idegtudományi Intézet / National Institute of Neurosciences
Budapest, , Hungary
University of Pécs Clinical Centre (PTE KK)
Pécs, , Hungary
AZ. Ospedaliero-Universitario-Ospedali Riuniti
Ancona, , Italy
AO Niguarda Ca' Granda
Milan, , Italy
AO Santa Maria della Misericordia di Udine
Udine, , Italy
SEIN Heemstede
Heemstede, , Netherlands
Expertisecentrum Voor Epileptologie-Kempenhaeghe
Heeze, , Netherlands
SEIN
Zwolle, , Netherlands
Szpital Uniwersytecki w Krakowie - Neurology
Krakow, , Poland
Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
Lublin, , Poland
Hospital de Santa Maria
Lisbon, , Portugal
Centro Hospitalar de São João E.P.E.
Porto, , Portugal
Federal center of neurosurgery
Tyumen, , Russia
Karolinska University Hospital
Stockholm, , Sweden
Klinisk Neurovetenskap
Umeå, , Sweden
Uppsala Akademiska Hospital
Uppsala, , Sweden
Frenchay Hospital
Bristol, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Peltola J, Colon AJ, Pimentel J, Coenen VA, Gil-Nagel A, Goncalves Ferreira A, Lehtimaki K, Ryvlin P, Taylor RS, Ackermans L, Ardesch J, Bentes C, Bosak M, Burneo JG, Chamadoira C, Elger CE, Eross L, Fabo D, Faulkner H, Gawlowicz J, Gharabaghi A, Iacoangeli M, Janszky J, Jarvenpaa S, Kaufmann E, Kho KH, Kumlien E, Laufs H, Lettieri C, Linhares P, Noachtar S, Parrent A, Pataraia E, Patel NK, Peralta AR, Racz A, Campos AR, Rego R, Ricciuti RA, Rona S, Rouhl RPW, Schulze-Bonhage A, Schuurman R, Sprengers M, Sufianov A, Temel Y, Theys T, Van Paesschen W, Van Roost D, Vaz R, Vonck K, Wagner L, Zwemmer J, Abouihia A, Brionne TC, Gielen F, Boon PAJM; MORE Study Group. Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Drug-Resistant Epilepsy in the MORE Multicenter Patient Registry. Neurology. 2023 May 2;100(18):e1852-e1865. doi: 10.1212/WNL.0000000000206887. Epub 2023 Mar 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Addendum C.AD.1
Identifier Type: OTHER
Identifier Source: secondary_id
1.02.9001
Identifier Type: -
Identifier Source: org_study_id